Search fresh public links, source activity, and ready-to-use post angles for Specialty Drugs.
Fresh curated links around Specialty Drugs are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Specialty pharmacy is a key cost driver for employers and insurers, with development in this space showing no signs of slowing down.
Cigna is ramping up investments in specialty pharmacy and a companywide focus into better ways to manage complex care of patients in its health plans.
By Bryce Platt, PharmD For more than a decade, the answer to “Where do drug wholesalers make their money?” has been generic drugs. Although wholesaler revenues are linked mo...
By Tyler Novotny and Bryce Platt PBM-affiliated private label biosimilars would seem to have a built-in formulary advantage. But for ustekinumab, that advantage has not carrie...
Three federal pricing changes are about to land on a single outpatient claim. The largest infusion and oncology programs will feel them first, and hardest. Most of the 340B debate...
A new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effect...
EBRI's new research gives benefits brokers hard data on site-of-care waste in employer health plans
On October 12, 2026, Drug Channels Institute will release our 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. The U.S. prescription drug marke...
An analysis of commercial claims for 106 physician-administered outpatient drugs suggests $101 of additional plan spending per member per year stemming from site-of-treatment pay d...
Drug Channels Institute is pleased to announce the availability of our 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. The U.S. prescription d...
Eligible products for the zero per cent tariff rate include all drugs designated for rare diseases, infertility treatments, cell therapies, gene therapies, antibody-drug conjugates...
(StatePoint) Biological drug products (biologics) — which can be made of sugars, proteins, living cells, tissues, or a combination of these — are providing new options for patients...
The list of approved participants and drugs is larger than the controversial pilot's first attempted launch. It comes the same day that CMS launched a soon-to-be-mandatory data rep...
A 30-day supply of Xtandi for prostate cancer runs $13,480 right now, before your Medicare plan touches it. Tradjenta for type 2 diabetes rings up at $488. Starting January 1, 2027...
A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a note...
Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially more selectively than — Rhythm Pharmaceuticals...
A 100% US tariff on covered patented pharmaceuticals expands with generics excluded and select specialty medicines from India exempted Read Full Article at RT.com
This week, we're rerunning some popular posts while we put the finishing touches on DCI’s 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Clic...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.